摘要
糖尿病(DM)合并心力衰竭(HF)患者在临床上治疗和生存状态较差,而不同的降糖药物导致HF的风险不同。本文综述总结了目前各类降糖药物临床实验中对HF的影响:二甲双胍是一种相对安全的降糖药物;钠-葡萄糖共转运体-2(SGLT-2)抑制剂类降糖药可以降低危重心血管病和HF的风险,未来有望用于一线治疗,以改善HF患者的预后。
The clinical treatment and survival status of diabetic (DM) patients with heart failure (HF) is poor, and studies have shown that different hypoglycemic drugs have different risks of causing HF. In order to provide references for clinical drug use and improve the prognosis of patients aforesaid, the authors summarized the effects of various hypoglycemic drugs on HF in clinical trials as follow: metformin is a relatively safe hypoglycemic drug;sodium glucose co-transporter 2 (SGLT-2) inhibitors can reduce the risk of major cardiovascular disease and HF, and may be used as a potential first-line therapy to improve the prognosis of heart failure, which has a broad prospect and value.
作者
刘霞
施青青
张丽红
LIU Xia;SHI Qingqing;ZHANG Lihong(Special Medical Center of PAP,Tianjin 300162,China)
出处
《药学与临床研究》
2019年第5期374-376,共3页
Pharmaceutical and Clinical Research
